Checkpoint inhibition (e.g., PD-1/PD-L1 and CTLA-4 blockade) has demonstrated efficacy in human papillomavirus (HPV)-associated cancers and may be adapted for veterinary applications. This evidence concerns the gene CTLA4 and cancer.